Intraportal and systemic allogeneic cell therapy in a murine model of hepatic metastatic breast cancer

References

• Baur M, Schlappack O, Havelec et al, Prognostic significance of liver metastasis as first sign of generalization in patients with breast cancer. Acta Med Austrica (2001) 28: 135–40.
   Google Scholar
• Saenz NC, Cady B, McDermott Jr WV et al, Experience with colorectal carcinoma metastatic to the liver. Surg Clin North Am (1989) 69: 361–70.
   Google Scholar
• Herzig RH, Lynch J, Christiansen NP et al, Dose-intensive chemotherapy with etoposide-cyclophosphamide for advanced breast cancer. Semin Oncol (1996) 23: 28–32.
   Google Scholar
• Stadtmauer EA, O’Neill A, Goldstein LJ et al, Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med (2000) 342: 1069–76.
   Google Scholar
• Roh MS, Kahky MP, Oyedeji C et al, Murine Kupffer cells and hepatic natural killer cells regulate tumor growth in a quantitative model of colorectal liver metastasis. Clin Exp Metastasis (1992) 10: 317–27.
   Google Scholar
• Wisse E, Luo D, Vermijlen D et al, On the function of pit cells, the liver-specific natural killer cells. Semin Liver Dis (1997) 17: 265–86.
   Google Scholar
• Nakagawa R, Motoki K, Ueno H et al, Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000. Cancer Res (1998) 58(15): 1202–7.
   Google Scholar
• Endo S, Kinoshito J, Yoshimatsu K et al, Intrahepatic lymphocyte analysis and assessment of the effects of levamisole in murine hepatic metastasis model. Anticancer Res (1998) 18: 907–10.
   Google Scholar
• Peron JM, Esche C, Subbotin VM et al, FLT3-ligand administration inhibits liver metastasis: role of NK cells. J Immunol (1998) 161: 6164–70.
   Google Scholar
• Hirschowitz EA, Naama HA, Evoy D et al, Regional treatment of hepatic micrometastasis by adenovirus vector-mediated delivery of interleukin-2 and interleukin-12 cDNA to the hepatic parenchyma. Cancer Gene Ther (1999) 6: 491–8.
   Google Scholar
• Lygidakis NJ, Sgourakis G, Vlachos L et al, Metastatic liver disease of colorectal origin: the value of locoregional immunotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study. Hepatogastroenterology (2001) 48: 1685–91.
   Google Scholar
• Cohen P, Vourka-Karussis U, Weiss L, Slavin S, Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens. J Immunol (1993) 151: 4803–10.
   Google Scholar
• Slavin S, Naperstek E, Nagler A et al, Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol (1995) 23: 1553–62.
   Google Scholar
• Slavin S, Naperstek E, Nagler A et al, Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation. Blood (1996) 87: 2195–204.
   Google Scholar
• Slavin S, Immunotherapy of cancer with alloreactive lymphocytes. N Engl J Med (2000); 343: 802–3: comments on N Engl J Med (2000) 343: 750–8.
   Google Scholar
• Morecki S, Yakovelev E, Diab A, Slavin S, Allogeneic cell therapy for a murine mammary carcinoma. Cancer Research (1998) 58: 3891–5.
   Google Scholar
• Morecki S, Yacovlev E, Gelfand Y et al, Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma. J Immunother (2001) 24: 114–21.
   Google Scholar
• Ben Yosef R, Or R, Nagler A, Slavin S, Graft-vs-tumor and graft-vs-leukemia in patient with concurrent breast cancer and acute myelocytic leukemia. Lancet (1996) 16(348): 1242–3.
   Google Scholar
• Or R, Ackerstein A, Nagler A, Allogeneic cell mediated immunotherapy for patients after autologous stem cell transplantation. Cytokines Cell Mol Ther (Lond) (1998) 4: 1–6.
   Google Scholar
• Eible B, Schwaighofer H, Nachbaur D et al, Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood (1996) 8: 1501–8.
   Google Scholar
• Ueno NT, Rondon G, Mirza NQ et al, Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol (1998) 16: 986–93.
   Google Scholar
• Childs R, Chernoff A, Contentin N et al, Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med (2000) 343: 750–8.
   Google Scholar
• Dexter D, Kowalski HM, Blazar BA et al, Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res (1978) 38: 3174–81.
   Google Scholar
• Pulaski BA, Ostrand-Rosenberg S, Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccine. Cancer Res (1998) 58: 1486–93.
   Google Scholar
• Kaplan E, Meier P, Non-parametric estimation from incomplete observation. J Am Stat Assoc (1958) 53: 457–82.
   Google Scholar
• Mantel E, Evaluation of survival data and two new rank orders statistics arising in its consideration. Cancer Chemother (1966) 50: 163–70.
   Google Scholar
• Kjaergaard J, Hokland ME, Agger R et al, Biodistribution and tumor localization of lymphokine-activated killer T cells following different routes of administration in tumor-bearing animal. Cancer Immunol Immunother (2000) 48: 550–60.
   Google Scholar
• Eid A, Morecki, Slavin S, Induction of transplant tolerance by intraportal injection of allogeneic bone marrow cells possible implications for intrauterine bone marrow transplantation across major histocompatibility barriers. Transplant Int (1988) 1: 109–12.
   Google Scholar
• Qian JH, Kokudo S, Sato S et al, tolerance induction of alloreactivity by portalvenous inoculation with allogeneic cells followed by the injection of cyclophosphamide. Transplantation (1987) 43: 538–42.
   Google Scholar
• Morecki S, Slavin S, Toward amplification of a graft-versus-leukemia effect while minimizing graft-versus-host disease. J Hematother Stem Cell Res (2000) 9: 355–66.
   Google Scholar
• Sullivan KM, Weiden PL, Storb R et al, Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood (1989) 73: 1720–6.
   Google Scholar
• Bortin MM, Truitt RL, Rimm AA, Bach FH, Graft-versus-leukemia reactivity induced by alloimmunization without augmentation of graft-versus-host reactivity. Nature (1979) 281: 490–1.
   Google Scholar
• Slavin S, Weiss L, Morecki S, Weigensberg M, Eradication of murine leukemia with histocompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol Immunother (1981) 11: 155–61.
   Google Scholar
• Meredith RF, Okunewick JP, Possibility of graft-vs-leukemia determinants independent of the major histocompatibility complex in allogeneic marrow transplantation. Transplantation (1983) 35: 378–85.
   Google Scholar
• Slavin S, Naparstek E, Nagler A et al, Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol (1995) 23: 1553–62.
   Google Scholar
• Yang YG, Sergio JJ, Pearson DA et al, Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice. Blood (1997) 90: 4651–560.
   Google Scholar
• Teshima T, Hill GR, Pan L et al, IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J Clin Invest (1999) 104: 317–25.
   PubMed Web of Science ®Google Scholar
• Prigozhina TB, Gurevitch O, Morecki S et al, Nonmyeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in preclinical models. Exp Hematol (2002) 30: 89–96.
   Google Scholar
• Weiss L, Reich S, Slavin S, Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy. Cancer Invest (1992) 10: 19–26.
   Google Scholar
• Naparstek E, Nagler A, Or R et al, Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies. Clin Transpl (1996) 24: 281–90.
   Google Scholar
• Uharek L, Glass B, Gaska T et al, Natural killer cells as effector cells of graft-versus-leukemia activity in a murine transplantation model. Bone Marrow Transplant (1993) 12(Suppl 3): S57–60.
   Google Scholar
• Ruggeri L, Capanni M, Casucci M et al, Role of natural killer cell alloreactivity in HLA mismatched hematopoietic stem cell transplantation. Blood (1999) 94: 333–9.
   Google Scholar
• Falkenberg JH, Wafelman AR, Joosten P et al, Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood (1999) 94: 1201–8.
   Google Scholar
• Morecki S, Slavin S, Ben-Sasson SA, Selective abrogation of alloreactivity via priming in the presence of aphidicolin, a specific inhibitor of DNA polymerase. J Immunol (1989) 143: 838–43.
   Google Scholar
• Bonini C, Ferrari G, Verzeletti S et al, HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science (1997) 276: 1719–24.
   Google Scholar